Literature DB >> 7333447

Follow-up study in chronic active hepatitis after therapies with immunosuppressive drugs and tiopronin.

T Tsuji, H Nagashima.   

Abstract

Follow-up studies were conducted in the patients with chronic active hepatitis treated 10 years ago with tiopronin (TP) or corticosteroids (CS). HB surface antigen (HBsAg) was measured in previously collected paraffin embedded liver sections by enzyme-labelled antibody technique. Of 72 cases examined, 15 cases were treated with TP only (8 cases) and combination with CS (7 cases), 38 cases with CS and 19 cases not treated with TP or CS (control group). Two deaths occurred in TP group (each 1 case in the single and combination treatments) in the 9th year due to bleeding of oesophageal varices in a chronic aggressive hepatitis (2B type) with HBsAg diffusely distributed in liver tissue. Two deaths were found in CS group and 4 in the control group. No significant difference as noted in the rehabilitation rate in HBsAg negative cases of TP group and CS group versus the control group. In the positive cases, the rehabilitation rate was found to be 66.7% in the CS group compared with 0% in the non-CS group, and each 3 cases out of 5 rehabilitated by the single and combination treatments with TP respectively.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333447     DOI: 10.1007/bf02813791

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  10 in total

1.  Detection of HBs antigen in routine paraffin embedded liver tissue by enzyme-labelled antibody technique.

Authors:  T Tsuji; K Naito; K Tokuyama; T Okada; K Kosaka
Journal:  Acta Med Okayama       Date:  1976-02       Impact factor: 0.892

2.  Controlled trial of prednisone and azathioprine in active chronic hepatitis.

Authors:  I M Murray-Lyon; R B Stern; R Williams
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

3.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

4.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

5.  Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

Authors:  G C Cook; R Mulligan; S Sherlock
Journal:  Q J Med       Date:  1971-04

6.  Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution.

Authors:  A H Baggenstoss; R D Soloway; W H Summerskill; L R Elveback; L J Schoenfield
Journal:  Hum Pathol       Date:  1972-06       Impact factor: 3.466

7.  Classification and treatment of chronic active liver disease.

Authors:  M G Geall; L J Schoenfield; W H Summerskill
Journal:  Gastroenterology       Date:  1968-12       Impact factor: 22.682

8.  Immunosuppressive activity in patients with active chronic hepatitis and primary biliary cirrhosis treated with azathioprine.

Authors:  G Whelan; S Sherlock
Journal:  Gut       Date:  1972-11       Impact factor: 23.059

9.  Follow-up ten years after corticosteroid therapy for chronic active hepatitis type B.

Authors:  T Tsuji; K Naito; K Tokuyama; T Okada; S Takata; K Araki; T Shinohara; J Inoue; K Onoue; M Tsuchiya; H Nozaki; H Nagashima; K Hamaya
Journal:  Hepatogastroenterology       Date:  1980-04

10.  A case report of primary hepatic carcinoma with prolonged HB virus infection and mono-clonal gammopathy.

Authors:  T Tsuji; K Tokuyama; K Naito; S Okazaki; T Shinohara
Journal:  Gastroenterol Jpn       Date:  1977
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.